Arrowhead puts pressure on Ionis with positive data for triglyceride lowering drug

Phase 3positiveplozasiranTryngolzaPositive

AI Analysis

Summary

Arrowhead Pharmaceuticals announced positive Phase 3 data for plozasiran showing a potentially best-in-class profile for triglyceride lowering, with plans to submit for FDA approval by end of 2026. The company aims to compete with Ionis' recently approved Tryngolza for severe hypertriglyceridemia treatment.

Clinical Trial Data

Phase

Phase 3

Primary Endpoint

Met

Outcome Details

Phase 3 data showing potentially best-in-class profile

Importance:7/10

Sentiment:

0.70

Phase 3 datatriglyceride loweringFDA approval plannedcompetitive pressurehypertriglyceridemia

Related Companies

$IONS

Read the original article

Published by BioSpace on July 22, 2026 2:28 PM

Read Original